The Role of Circulating Biomarkers in the Oncological Management of Metastatic Renal Cell Carcinoma: Where Do We Stand Now?

Renal cell carcinoma (RCC) is an increasingly common malignancy that can progress to metastatic renal cell carcinoma (mRCC) in approximately one-third of RCC patients. The 5-year survival rate for mRCC is abysmally low, and, at the present time, there are sparingly few if any effective treatments. C...

Descripción completa

Detalles Bibliográficos
Autores principales: Cinque, Alessandra, Capasso, Anna, Vago, Riccardo, Lee, Michael W, Floris, Matteo, Trevisani, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773056/
https://www.ncbi.nlm.nih.gov/pubmed/35052770
http://dx.doi.org/10.3390/biomedicines10010090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773056/
https://www.ncbi.nlm.nih.gov/pubmed/35052770
http://dx.doi.org/10.3390/biomedicines10010090

Ejemplares similares